JP2009504746A - 第Ｘａ因子インヒビターのシクロデキストリン包接複合体 - Google Patents

第Ｘａ因子インヒビターのシクロデキストリン包接複合体 Download PDF

Info

Publication number
JP2009504746A
JP2009504746A JP2008527053A JP2008527053A JP2009504746A JP 2009504746 A JP2009504746 A JP 2009504746A JP 2008527053 A JP2008527053 A JP 2008527053A JP 2008527053 A JP2008527053 A JP 2008527053A JP 2009504746 A JP2009504746 A JP 2009504746A
Authority
JP
Japan
Prior art keywords
formulation
amount
cyclodextrin
factor
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008527053A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009504746A5 (https=
Inventor
ムニール・エヌ・ナッサー
ウダイ・シャンカー・ゴゲイト
ティモシー・エム・マロイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2009504746A publication Critical patent/JP2009504746A/ja
Publication of JP2009504746A5 publication Critical patent/JP2009504746A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2008527053A 2005-08-17 2006-08-16 第Ｘａ因子インヒビターのシクロデキストリン包接複合体 Withdrawn JP2009504746A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70907705P 2005-08-17 2005-08-17
US11/464,519 US20070191306A1 (en) 2005-08-17 2006-08-15 FACTOR Xa INHIBITOR FORMULATION AND METHOD
PCT/US2006/031801 WO2007022165A2 (en) 2005-08-17 2006-08-16 Factor xa inhibitor inclusion complex with cyclodextrin

Publications (2)

Publication Number Publication Date
JP2009504746A true JP2009504746A (ja) 2009-02-05
JP2009504746A5 JP2009504746A5 (https=) 2009-08-20

Family

ID=37654897

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008527053A Withdrawn JP2009504746A (ja) 2005-08-17 2006-08-16 第Ｘａ因子インヒビターのシクロデキストリン包接複合体

Country Status (10)

Country Link
US (2) US20070191306A1 (https=)
EP (1) EP1924291A2 (https=)
JP (1) JP2009504746A (https=)
AR (1) AR055377A1 (https=)
BR (1) BRPI0614827A2 (https=)
CA (1) CA2619214A1 (https=)
MX (1) MX2008002057A (https=)
PE (1) PE20070378A1 (https=)
TW (1) TW200800270A (https=)
WO (1) WO2007022165A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015521986A (ja) * 2012-06-27 2015-08-03 武田薬品工業株式会社 塩により安定化されたアミンおよび有機酸の液状製剤
JP2015531377A (ja) * 2012-09-26 2015-11-02 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アピキサバン液体製剤
JP2016537424A (ja) * 2013-11-18 2016-12-01 チュヨンドゥ イーストン バイオファーマシューティカルズ カンパニー リミテッドＣｈｅｎｇｄｕ Ｅａｓｔｏｎ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． ピリジン誘導体及びその医学的使用
JP2019511575A (ja) * 2016-04-04 2019-04-25 ロクソ オンコロジー， インコーポレイテッドＬｏｘｏ Ｏｎｃｏｌｏｇｙ， Ｉｎｃ． （Ｓ）−Ｎ−（５−（（Ｒ）−２−（２，５−ジフルオロフェニル）−ピロリジン−１−イル）−ピラゾロ［１，５−ａ］ピリミジン−３−イル）−３−ヒドロキシピロリジン−１−カルボキサミドの液体製剤

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074052A1 (es) 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
SMT202000093T1 (it) * 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
IN2012DN06587A (https=) * 2010-02-25 2015-10-23 Bristol Myers Squibb Co
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
ES2836222T3 (es) 2016-05-18 2021-06-24 Loxo Oncology Inc Preparación de (S)-N-(5-((R)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
CN115715770B (zh) * 2021-08-24 2024-01-26 新领医药技术(深圳)有限公司 阿哌沙班透皮贴剂及其制备方法
NL2029536B1 (en) 2021-10-27 2023-05-26 Pharma Data S A Apixaban suspension and preparation method
US12214075B2 (en) 2021-10-27 2025-02-04 Pharma-Data Research And Development Single Member S.A. Apixaban suspension and preparation method
WO2026003874A1 (en) * 2024-06-28 2026-01-02 Cipla Limited Injectable compositions of apixaban

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US4745105A (en) * 1986-08-20 1988-05-17 Griffin Charles C Low molecular weight heparin derivatives with improved permeability
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
JPH10194996A (ja) * 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
FR2773801B1 (fr) * 1998-01-19 2000-05-12 Sanofi Sa Nouveaux pentasaccharides, procedes pour leurs preparations et compositions pharmaceutiques les contenant
DE60006407T2 (de) * 1999-09-13 2004-09-09 3-Dimensional Pharmaceuticals, Inc. Azazykloalkanone serin-protease-hemmer
TWI331526B (en) * 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
CA2461202C (en) * 2001-09-21 2011-07-12 Donald Pinto Lactam-containing compounds and derivatives thereof as factor xa inhibitors

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015521986A (ja) * 2012-06-27 2015-08-03 武田薬品工業株式会社 塩により安定化されたアミンおよび有機酸の液状製剤
JP2015531377A (ja) * 2012-09-26 2015-11-02 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アピキサバン液体製剤
US10016362B2 (en) 2012-09-26 2018-07-10 Bristol-Myers Squibb Company Apixaban liquid formulations
JP2016537424A (ja) * 2013-11-18 2016-12-01 チュヨンドゥ イーストン バイオファーマシューティカルズ カンパニー リミテッドＣｈｅｎｇｄｕ Ｅａｓｔｏｎ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． ピリジン誘導体及びその医学的使用
JP2019511575A (ja) * 2016-04-04 2019-04-25 ロクソ オンコロジー， インコーポレイテッドＬｏｘｏ Ｏｎｃｏｌｏｇｙ， Ｉｎｃ． （Ｓ）−Ｎ−（５−（（Ｒ）−２−（２，５−ジフルオロフェニル）−ピロリジン−１−イル）−ピラゾロ［１，５−ａ］ピリミジン−３−イル）−３−ヒドロキシピロリジン−１−カルボキサミドの液体製剤
JP7061602B2 (ja) 2016-04-04 2022-04-28 ロクソ オンコロジー， インコーポレイテッド （Ｓ）－Ｎ－（５－（（Ｒ）－２－（２，５－ジフルオロフェニル）－ピロリジン－１－イル）－ピラゾロ［１，５－ａ］ピリミジン－３－イル）－３－ヒドロキシピロリジン－１－カルボキサミドの液体製剤

Also Published As

Publication number Publication date
US20090291913A1 (en) 2009-11-26
TW200800270A (en) 2008-01-01
MX2008002057A (es) 2008-04-16
BRPI0614827A2 (pt) 2011-04-19
WO2007022165B1 (en) 2007-10-18
PE20070378A1 (es) 2007-05-04
CA2619214A1 (en) 2007-02-22
AR055377A1 (es) 2007-08-22
EP1924291A2 (en) 2008-05-28
WO2007022165A2 (en) 2007-02-22
US20070191306A1 (en) 2007-08-16
WO2007022165A3 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
US20090291913A1 (en) FACTOR Xa INHIBITOR FORMULATION AND METHOD
KR100720886B1 (ko) 주사용 실로스타졸 수성 제제
KR20040106452A (ko) 아미오다론 및 설포알킬 에테르 사이클로덱스트린을함유하는 제제
HU226778B1 (en) Injection and injection kit containing omeprazole and its analogs
JP6734971B2 (ja) がん治療薬
AU2003267788A1 (en) Novel injectable depot formulations
JP2018531268A (ja) ダントロレンを含む水性組成物
JP2018531268A6 (ja) ダントロレンを含む水性組成物
JP2015509528A (ja) ピロキシカムまたはその薬学的に許容される塩とヒアルロン酸またはその薬学的に許容される塩とを含む安定な液状の医薬組成物およびその製造方法
HUP0203121A2 (hu) Szubsztituált benzimidazolokat tartalmazó gyógyszerkészítmény és alkalmazása
WO1997039770A1 (en) New pharmaceutical formulation of a thrombin inhibitor for parenteral use
JP5113323B2 (ja) ジクロフェナクナトリウムとβ−シクロデキストリンとを有する注入可能薬学組成物
WO2008088816A1 (en) Adenosine derivative formulations for medical imaging
JP2009504746A5 (https=)
JP2006508917A (ja) メスナを有する、オキサザホスホリンの液体安定性組成物
CN101340933A (zh) 具有环糊精的因子xa抑制剂包合配合物
MXPA05005587A (es) Composicion liquida concentrada de valdecoxib.
US4968673A (en) Use of a thromboxane receptor antagonist in renal diseases and dysfunction
JP5462797B2 (ja) 注射可能なメクリジン製剤および方法
US20040087513A1 (en) New drug combinations based on sodium channel blockers and magnesium salts
CN1034132A (zh) 含哌啶基环戊基庚烯酸衍生物的水溶液配方
US5221695A (en) Aqueous formulation containing a piperidinylcyclopentylheptenoic acid derivative and beta-cyclodextrin
JP2005520856A (ja) 貯蔵時に安定なエプレレノン製剤
JP4275394B2 (ja) 注射用シロスタゾール水性製剤
EP1864664A1 (en) Pharmaceutical preparation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090630

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100511